Who are trastuzumab monotherapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pyrotinib in combination with Capecitabine., Trastuzumab SC, Trastuzumab/Hyaluronidase-oysk, TQB2440 injection + Trastuzumab + Docetaxel, Trastuzumab IV, Paclitaxel + Trastuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-monotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

trastuzumab monotherapy — Competitive Intelligence Brief

trastuzumab monotherapy (trastuzumab monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2/neu receptor antagonist. Area: Oncology.

phase 3 HER2/neu receptor antagonist HER2/neu Oncology Small molecule Live · refreshed every 30 min

Target snapshot

trastuzumab monotherapy (trastuzumab monotherapy) — Comprehensive Support Project for Oncology Research. Trastuzumab targets and binds to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
trastuzumab monotherapy TARGET	trastuzumab monotherapy	Comprehensive Support Project for Oncology Research	phase 3	HER2/neu receptor antagonist	HER2/neu
Pyrotinib in combination with Capecitabine.	Pyrotinib in combination with Capecitabine.	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Tyrosine kinase inhibitor	HER2/neu
Trastuzumab SC	Trastuzumab SC	Dana-Farber Cancer Institute	phase 3	HER2/neu receptor antagonist	HER2/neu
Trastuzumab/Hyaluronidase-oysk	Trastuzumab/Hyaluronidase-oysk	National Cancer Institute (NCI)	phase 3	Monoclonal antibody	HER2/neu receptor
TQB2440 injection + Trastuzumab + Docetaxel	TQB2440 injection + Trastuzumab + Docetaxel	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Targeted therapy, monoclonal antibody, chemotherapy	PD-1, HER2/neu
Trastuzumab IV	Trastuzumab IV	Hoffmann-La Roche	phase 3	Monoclonal antibody	HER2/neu receptor
Paclitaxel + Trastuzumab	Paclitaxel + Trastuzumab	Institut de cancérologie Strasbourg Europe	phase 3	Taxane + monoclonal antibody	Microtubules + HER2/neu receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2/neu receptor antagonist class)

Comprehensive Support Project for Oncology Research · 1 drug in this class
Dana-Farber Cancer Institute · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). trastuzumab monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-monotherapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab